KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) Research & Development (2017 - 2025)

Cardlytics' Research & Development history spans 9 years, with the latest figure at $8.0 million for Q4 2025.

  • For Q4 2025, Research & Development fell 19.5% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $39.8 million, down 19.84%, while the annual FY2025 figure was $39.8 million, 19.84% down from the prior year.
  • Research & Development reached $8.0 million in Q4 2025 per CDLX's latest filing, down from $8.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $14.8 million in Q2 2023 to a low of $6.2 million in Q1 2021.
  • Average Research & Development over 5 years is $11.7 million, with a median of $12.1 million recorded in 2021.
  • Peak YoY movement for Research & Development: soared 140.78% in 2021, then crashed 33.31% in 2025.
  • A 5-year view of Research & Development shows it stood at $11.8 million in 2021, then increased by 25.32% to $14.8 million in 2022, then decreased by 15.47% to $12.5 million in 2023, then decreased by 20.91% to $9.9 million in 2024, then fell by 19.5% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for CDLX's Research & Development are $8.0 million (Q4 2025), $8.8 million (Q3 2025), and $11.3 million (Q2 2025).